Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

March 26, 2010

Primary Completion Date

May 24, 2018

Study Completion Date

May 24, 2018

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Lenalidomide

10 mg d1-d21 of a 28-day cycle

Trial Locations (12)

12203

Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin

20246

Universitätsklinikum Hamburg Eppendorf, Hamburg

30625

Medizinische Hochschule Hannover, Hanover

37075

Universitätsklinikum Göttingen, Göttingen

40225

Heinrich Heine Universität Düsseldorf, Düsseldorf

47166

Kath. Klinikum Duisburg, Duisburg

60590

Klinikum der J.W. Goethe Universität, Frankfurt

68167

Universitätsklinikum Mannheim, Mannheim

79106

Universitätsklinikum Freiburg, Freiburg im Breisgau

81675

TU München - Klinikum rechts der Isar, München

89081

Universitätsklinikum Ulm, Ulm

01307

Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ClinAssess GmbH

INDUSTRY

lead

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

OTHER

NCT01081431 - Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q | Biotech Hunter | Biotech Hunter